noac: future perspectives: academic perspective€¦ · prof. hugo ten cate maastricht university...
TRANSCRIPT
![Page 1: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/1.jpg)
Prof. Hugo ten Cate Maastricht University Medical Centre
Maastricht the Netherlands
NOAC: Future perspectives: academic perspective
![Page 2: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/2.jpg)
To discuss
• Lessons from the NOAC-VKA studies and optimal VKA management
• How to improve the quality of NOAC?
![Page 3: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/3.jpg)
Cameron C et al. BMJ Open 2014;4:e004301
(A) stroke or systemic embolism B) major bleeding
*
*
*
*
*
![Page 4: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/4.jpg)
Wallentin et al, Lancet 2010
Mean TTR in NOAC studies
≥70
Wallentin et al. Lancet 2010, vol 376:975-83
![Page 5: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/5.jpg)
Quality VKA
• TTR of ≥70% is recommended in the
European Society of Cardiology
guidelines1
• Mean TTR ranged from 55–65% in the
warfarin arm of key trials of non-VKA
oral anticoagulants2-4
1. Camm AJ et al. Eur Heart J. 2012. 2.Patel MR et al. N Engl J Med. 2011.
3. Connolly SJ et al. N Engl J Med. 2009 4. Granger CB et al. N Engl J Med. 2011.
![Page 6: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/6.jpg)
Wallentin et al, Lancet 2010
TTR and effectiveness
Wallentin et al. Lancet 2010, vol 376:975-83
![Page 7: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/7.jpg)
TTR and Bleeding
cTTR> 72.6
Wallentin et al. Lancet 2010, vol 376:975-83
cTTR <57.1
![Page 8: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/8.jpg)
Intracranial hemorrhage
Sjogren, TH 2015
(n=68.797)Risk ICH red: per treatment year, blue: age groups
![Page 9: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/9.jpg)
Lessons from VKA
• TTR > 70% offers greater protection against TE stroke (and mortality) than poorly controlled VKA
• At TTR > 70% bleeding complications are acceptable (in Sweden)
• In NOAC trials the average comparator (warfarin) had a rather modest TTR (55-64%)
• So, why are we satisfied with non-inferior or limited superiority of NOAC as compared to suboptimal warfarin.
• Implication is that NOAC therapy should be improved!
![Page 10: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/10.jpg)
To tackle with NOAC
• Fixed dose; why not assess individual’s response and suitability for specific NOAC?
• Improve adherence
• How to monitor, reversal, thrombolysis, after recent stroke; when to resume; after ICH, in multi-morbid geriatric patients, during episodes of intercurrent disease..
ten Cate H. Thromb J. 2013 Jun 28;11(1):8. ten Cate H. Thromb Haemost. 2012 May;107(5):803-5. Hankey. Thromb Haemost 2014; 111: 808
![Page 11: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/11.jpg)
Does one size fit all?
![Page 12: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/12.jpg)
Reilly et al , J Am Coll Cardiol, 63 (4) 2014: 321 - 328.
Dabigatran trough & outcomes
![Page 13: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/13.jpg)
Levels & Patient characteristics
• Long-term FU RE-LY, 9183 pt, 112 isch. stroke (1.3%), 323 major bleed (3.8%)
• IS inversely related to trough (p=0.045),age and previous stroke (p<0.0001)
• Major bleed related to dabigatran overexposure (p<0.0001),age (p<0.0001) , ASA use (p<0.003) and diabetes (p<0.018)
Reilly et al. J Am Cardiol 2014;63:321-8
![Page 14: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/14.jpg)
Variability Dabigatran levels
Chan et al, Thromb Haemostas 2015: 13( 3), 353-359
![Page 15: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/15.jpg)
Edoxaban trough & outcomes
Ruff et al, Lancet 2015
![Page 16: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/16.jpg)
Levels_Riva20mg
<1 m
onth
3 mon
ths
6 mon
ths
12 m
onths
0
200
400
600
N=44
Leve
ls_R
ivar
oxab
an n
g/m
l
Rivaroxaban
Ten Cate-Hoek et al, unpublished
Median peak (IQR)
![Page 17: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/17.jpg)
Levels per patient over timeLevels_Rivaroxaban N=44
<1 m
onth
1 mon
th
3 mon
ths
6 mon
ths
12 m
onths
0
200
400
600
Leve
ls_R
ivar
oxab
an n
g/m
lRivaroxaban 20 mg
![Page 18: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/18.jpg)
Conclusion from PK analyses
• Data suggest that at least for dabigatran we should check dose-responses in individuals
• Data are sufficiently robust to merit assessing individual trough levels
• Instead of concentrations, quantitative assays may be used
• This cannot lead to individual dose optimization for a single NOAC beyond registered doses
![Page 19: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/19.jpg)
How to proceed?
• Informed decision on type of anticoagulant (VKA or NOAC)
• Assess optimal drug (and dose) response to determine whether drug X is appropriate using a quantitative assay (and/or concentration assay?).
• If trough is in extreme end (lower 10 or 20%): either tailoring to other dose or switch drug (other NOAC or VKA).
• If it is within range it provides a personal patient’s bench mark for unanticipated situations
![Page 20: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/20.jpg)
New studies: what is the basis?
• We need all available data on dose response relationships from the large trials on all NOAC, including for concentrations and activity assays (PT, TG etc); therapeutic ranges!
• Analysis of such data could provide sufficient information to decide on the necessity of PK based NOAC selection
• In practice: “PK” options may be limited: settle for trough or peak (eg in odd dosed NOAC)
![Page 21: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/21.jpg)
New studies 2?
• For each patient benchmark data on “PK” are useful
• In case of registries such information could be linked to outcomes to obtain additional and “real life” data
• Specific problems require study of NOAC concentration/activity levels: intercurrent illness requiring hospitalization/antibiotic treatment/ dehydration/ bleeding and trhomboemboliccomplications etc.
• Why? To make better informed decisions on drug management!
![Page 22: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/22.jpg)
Heidbuchel H et al. Europace 2013;15:625-651
Structured FU
Structured follow-up of patients on NOACs.
It is mandatory to ensure safeand effective drug intake.
![Page 23: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/23.jpg)
Conclusions
• NOAC (and VKA) treatment should be improved
• Optimize drug and dose selection based on individual criteria (also including PK)
• Optimize long term follow up
• Investigate consequences of intercurrent illness on anticoagulant management (TE, bleeding, infectious diseases, congestive heart failure etc)
![Page 24: NOAC: Future perspectives: academic perspective€¦ · Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands NOAC: Future perspectives: academic perspective](https://reader033.vdocument.in/reader033/viewer/2022042310/5ed892b76714ca7f47682d43/html5/thumbnails/24.jpg)